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Biomarkera b s t r a c t
Although the epidemiology of high-density lipoprotein (HDL) cholesterol and cardiovascular risk has
been consistent, pharmacologic interventions to increase HDL-cholesterol by delaying HDL catabolism
did not translate into reduction in cardiovascular risk. HDL particles are small, protein-rich when com-
pared to other plasma lipoprotein classes. Latest progresses in proteomics technology have dramatically
increased our understanding of proteins carried by HDL. In addition to proteins with well-established
functions in lipid transport, iron transport proteins, members of the complement pathway, and proteins
involved in immune function and acute phase response were repeatedly identiﬁed on HDL particles. With
the unraveling of the complexity of the HDL proteome, different laboratories have started to monitor its
changes in various disease states. In addition, dynamic aspects of HDL subgroups are being discovered.
These recent studies clearly illustrate the promise of HDL proteomics for deriving new biomarkers for dis-
ease diagnosis and to measure the effectiveness of current and future treatment regimens. This review
summarizes recent advances in proteomics and lipidomics helping to understand HDL function in health
and disease.
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
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Lipids are distributed in the human body by a complex lipid
transport system consisting of ﬁve main classes of lipoproteins
which, in order of molecular size, largest to smallest, are
chylomicrons, very low-density lipoproteins, intermediate-density
lipoproteins, low-density lipoproteins (LDL), and high-density lipo-
proteins (HDL) [1]. Plasma levels of LDL-cholesterol are causally
involved in the development of atherosclerosis and cardiovascular
disease. LDL transfers cholesterol to peripheral tissue and lowering
LDL-cholesterol by statins in people with pre-existing cardiovascu-
lar disease is effective in decreasing mortality [2,3].
HDL is the smallest of the lipoprotein particles containing the
highest proportion of apolipoproteins to lipids. The major HDL
associated apolipoproteins A-I (apoA-I) and apoA-II are secreted
into plasma by the liver and the intestine, where they are lipidated
to form lipid poor, discoidal, nascent HDL [4]. Nascent HDL takes
up cholesterol from cell membranes and other lipoproteins. Leci-
thin-cholesterol acyltransferase (LCAT) converts free cholesterol
into cholesteryl-ester thereby remodeling the particle to a spheri-
cal shape. Epidemiological studies have clearly shown that levels of
HDL-cholesterol are inversely associated with the risk of coronary
artery disease (CAD) and its thrombotic complications [5]. Conse-
quently, it was assumed that HDL-cholesterol raising therapies
could potentially further reduce cardiovascular mortality. Unex-
pectedly, pharmacologic interventions to increase HDL-cholesterol
by delaying HDL catabolism did not translate into reduction in car-
diovascular risk. The inability of HDL-cholesterol raising therapies
and new insights into the complexity of HDL composition and
function have prompted researchers to redeﬁne the understanding
of how HDL might exert its cardioprotective functions [6,7]. Recent
studies clearly showed that inﬂammation is a critical parameter in
modifying the proteome and lipidome of HDL [8–10]. HDL is most
widely recognized for its ability to transport cholesterol from the
periphery to the liver for excretion during the process of reverse
cholesterol transport (RCT). Numerous studies have shown that
HDL and several of its apolipoproteins can promote lipid efﬂux
from macrophages and other cells via several mechanisms
[11–13] and deliver cholesteryl-esters to the liver in the process
of selective uptake [13]. Studies in animals have consistently
shown that HDL is protective on several processes involved in ath-
erosclerosis, at least in part by mediating the removal of choles-
terol from lipid-laden macrophages. In mice, genetic lowering of
plasma HDL decreases the appearance of macrophage-derived cho-
lesterol in the feces [14] and transgenic expression of apoA-I
increases HDL and suppresses atherosclerosis in the apoE deﬁcient
mouse [15–17]. In humans, regressive changes in human athero-
sclerotic plaques were reported in relatively small studies when
reconstituted HDL or apoA-I was provided exogenously [18–21].
However, the mechanisms by which HDL may impact cardiovascu-
lar health and disease are complex and remain to be fully
understood.2. Novel insights into potential protective activities of HDL
2.1. HDL mediated cholesterol removal from the vessel wall
Removal of cholesterol from peripheral tissues to the blood-
stream via RCT is a process of major biological importance and is
believed to be a main reason how HDL might prevent cardiovascu-
lar disease. Active export of excess cholesterol to lipid-poor apoA-I
and lipid-enriched mature HDL is mediated by the ATP-binding
cassette transporters ABCA1 and ABCG1/G4 [22] (Fig. 1). In situa-
tions of excess cellular cholesterol, the nuclear liver X receptors
induce the transcription of ABCA1 and ABCG1 and thus cholesterol
efﬂux. In addition, tethering of HDL to SR-BI and aqueous diffusion
facilitates cholesterol efﬂux [23].
Of particular interest is the recent observation that the
lymphatic vessel route is critical for efﬁcient RCT from multiple
tissues, including the aortic wall [24] (Fig. 1). This challenges
the current view that lymphatic endothelium is a passive
exchange barrier for cholesterol transport. Removal of cholesterol
by lymphatic vessels is dependent on the uptake and transcytosis
of HDL by SR-BI expressed on lymphatic endothelium [24,25].
These results suggest that supporting lymphatic transport func-
tion may facilitate cholesterol clearance in therapies aimed at
reversing atherosclerosis.
The cholesterol taken up by HDL is esteriﬁed by LCAT and
transported to the liver directly and indirectly via two major path-
ways (Fig. 1). In humans, CETP transfers HDL-cholesteryl esters to
apoB-containing lipoproteins, which then are removed by the LDL
receptor pathway or the liver-independent transintestinal excre-
tion of cholesterol [26]. RCT thus also involves both formation
and catabolism of LDL. Signiﬁcant proportions of HDL-cholesterol
are removed by selective uptake through SR-BI into the liver and
steroidogenic organs [27].
2.2. Recent evidence links cholesterol efﬂux capability with
anti-inﬂammatory activities of HDL
Although it is clear that macrophage foam cell formation and
macrophage inﬂammation are both central processes in athero-
genesis, the detailed mechanisms linking these processes remain
incompletely understood. HDL has been shown to have anti-
inﬂammatory and anti-oxidative properties itself [28]. For exam-
ple, the major proteins of HDL, apoA-I and apoA-II, as well as
other proteins such as LCAT, paraoxonase and lipoprotein associ-
ated phospholipase A2 that cotransport with HDL in plasma, are
known to have antioxidant properties [29,30]. As a consequence,
HDL has the capacity to inhibit the oxidative modiﬁcation of LDL
thereby reducing the atherogenic properties of these lipoproteins.
HDL also possesses anti-inﬂammatory properties itself, by inhib-
iting adhesion molecules expression in endothelial cells and
thereby reducing the recruitment of blood monocytes into the
artery wall (Fig. 1) [28,31]. An interesting cellular mode of action
Fig. 1. Potential atheroprotective activities of HDL in the development of atherosclerotic lesions. Inhibitory activities of HDL are shown in red and activating/promoting HDL
activities in green. (1) HDL has the ability to inhibit monocyte adhesion by inhibiting vascular cell adhesion molecule (VCAM-1), intercellular cell adhesion molecule (ICAM-
1), and E-selectin expression and (2) suppresses monocyte chemotaxis by inhibiting chemokine secretion, such as monocytic chemotactic protein-1 (MCP1). (3) HDL
promotes cholesterol efﬂux frommacrophage foam cells via the cholesterol exporter ATP-binding cassette transporter A1 (ABCA1), ABCG1 and scavenger receptor type 1 (SR-
BI) thereby (4) preventing excessive cholesterol accumulation and (5) the secretion of pro-inﬂammatory cytokines from lipid-laden macrophages. (6) HDL enters the
lymphatic vessels via SR-BI to promote reverse cholesterol transport. (7) HDL inhibits smooth muscle cells (SMC) proliferation and migration into the intima. (8) HDL binding
to endothelial SR-BI and presenting HDL associated sphingosine-1-phosphate (S1P) to endothelial S1P receptors (S1PR) activates endothelial nitric oxide synthase (eNOS). In
addition, HDL induced cholesterol efﬂux via ABCG1 reduces inhibitory interaction of eNOS with cavelon-1 (CAV1). (9) Activation of cholesterol efﬂux pathways by HDL via
ABCA1 and ABCG1 controls the proliferation of hematopoietic stem cells (HPSC).
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reside in the cholesterol-depleting effects of HDL. Cholesterol
efﬂux via ABCA1 and ABCG1 was shown to regulate the prolifer-
ation of hematopoietic stem cells and to suppress the production
of monocytes and neutrophils [32,33]. HDL-induced cholesterol
efﬂux from macrophages is associated with a suppressed produc-
tion of inﬂammatory cells, cytokines and chemokines in athero-
sclerotic lesions [33] (Fig. 1). In macrophages, HDL-induced
cholesterol efﬂux decreases foam cell formation and macrophage
inﬂammation, and consequently also the expression of cytokines
that instruct the bone marrow to produce monocytes and neutro-
phils and stimulate monocyte inﬁltration into atherosclerotic
plaques [34]. There is recent evidence that the cholesterol mobi-
lizing activity of HDL acts to suppress inﬂammatory signaling via
Toll-like receptors [35–37]. Since successful signal transduction
relies on proper membrane microdomains containing high con-
centrations of cholesterol and sphingolipids, it is tempting to
speculate that perturbation of these microstructures by HDL
may explain the observed anti-inﬂammatory effects in innate
immune cells. HDL-induced cholesterol removal disrupts the for-
mation of cholesterol enriched ordered plasma membrane
domains (lipid rafts) required for effective Toll-like receptor sig-
naling, at least in part by reducing MyD88-dependent Toll-like
receptor trafﬁcking to lipid rafts [35–37]. A more recent study
reported that HDL induces the transcriptional regulator ATF3 in
macrophages, thereby effectively downregulating the expression
of Toll-like receptor induced proinﬂammatory cytokines in vitro
and in vivo [38].2.3. Endothelial protective effects of HDL
Over the last decade, substantial progress has been made in
understanding how HDL exerts direct protective effects on the vas-
cular endothelium. It was initially recognized that HDL can vasod-
ilate precontracted aortic segments [39,40], which was explained
by the ability of HDL to activate endothelial nitric oxide synthase
(eNOS) and thereby increasing endothelial nitric oxide production.
Several studies have provided information about the molecular
basis of this reaction involving SR-BI and the lysophospholipid
receptor S1P3, leading to the parallel activation of phosphatidylin-
ositol 3-kinase, protein kinase B (Akt) and mitogen-activated pro-
tein-kinase signaling [39–41], resulting in phosphorylation of
eNOS and increased nitric oxide production (Fig. 1). There is also
evidence that the cholesterol mobilizing activity of HDL maintains
endothelial function in an ABCG1-dependent manner, preventing
active eNOS dimer disruption and cell adhesion molecule
expression [37,42]. HDL can inhibit cytokine-induced expression
of vascular cell adhesion molecule (VCAM-1), intercellular cell
adhesion molecule (ICAM-1), and E-selectin on human endothelial
cells [31,43]. These proteins mediate the adhesion of lymphocytes,
monocytes, and basophils to the vascular endothelium and
promote leukocyte-endothelial cell signal transduction. They are
therefore central in the development of atherosclerosis and other
inﬂammatory diseases [44]. Consistently, administration of apoA-
I or HDL reduces adhesion molecule expression and monocyte
inﬁltration in small animal models [45,46] and attenuates the
secretion of monocyte chemotactic protein 1 from endothelial
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inﬂammatory sites [47]. Importantly, two recent studies have
demonstrated that HDL-mediated eNOS activation is impaired in
patients with CAD and chronic heart failure [48,49]. It was
observed that post-translational modiﬁcations of HDL were associ-
ated with a reduced ability to induce eNOS phosphorylation and
activation. Post-translational modiﬁcations of HDL, such as oxida-
tion by myeloperoxidase, carbamylation, malondialdehyde forma-
tion and advanced glycation end products have been shown to
decrease anti-atherogenic activities of HDL during inﬂammation
[10,48,50,51]. Myeloperoxidase derived reactive chlorinating spe-
cies target HDL associated plasmalogens generating HDL associ-
ated 2-chlorohexadecanal [52]. 2-Chlorohexadecanal was found
to directly impair eNOS activity by promoting an intracellular dis-
localization of eNOS [52]. However, it remains difﬁcult to ascertain
a speciﬁc post-translational protein or lipid modiﬁcation as causal,
since they occur simultaneously and may have accumulative
effects.
In addition, HDL has been shown to inhibit endothelial cell
apoptosis induced by modiﬁed lipoproteins, tumor necrosis factor
alpha, angiotensin II and oxidative stress, [53,54]. Several HDL-
associated mediators with anti-apoptotic activity have been iden-
tiﬁed. Puriﬁed apoA-I, the major protein constituent of HDL, or
HDL associated clusterin are suggested to attenuate apoptotic
intracellular signaling [55,56]. The impact of the lipid moiety of
HDL on its anti-apoptotic potential is less studied. Lysosphingoli-
pids, in particular sphingosine-1-phosphate, have been shown to
protect endothelial cells from apoptosis [57].2.4. The failure of recent HDL-cholesterol raising drugs
Given that several prospective observational studies have
shown a strong inverse relationship between HDL-cholesterol
and cardiovascular risk, HDL-cholesterol raising therapies were
expected to reduce cardiovascular mortality. This assumption
was supported by evidence from preclinical and (limited) clinical
studies showing that HDL is able to promote the regression of ath-
erosclerosis when the levels of functional particles are increased
from endogenous or exogenous sources [58]. Unexpectedly, drugs
increasing HDL-cholesterol by delaying HDL catabolism, such as
inhibitors of cholesteryl-ester transfer protein (CETP) or niacin
have failed to signiﬁcantly reduce the risk of major cardiovascular
events, especially when combined with statins [59]. Moreover,
genetic analysis did not show a causal association between genet-
ically raised plasma HDL-cholesterol levels and risk of myocardial
infarction [60]. Those ﬁndings prompt the suggestion that the com-
position and function of HDL may be more important to disease
outcome than the quantity of HDL-cholesterol itself. Direct mea-
sures of HDL composition and function are needed rather than
relying on surrogate markers such as the concentration of HDL-
cholesterol for assessing cardiovascular disease risk [6]. In line
with that assumption are the recent observations that the inverse
relationship of HDL-cholesterol with cardiovascular mortality is
markedly weakened in patients with CAD and that HDL-cholesterol
concentration is not an appropriate biomarker in the secondary
prevention setting [61]. Therefore, the usefulness of considering
HDL-cholesterol for cardiovascular risk stratiﬁcation seems limited
in such patients and more informative markers of HDL-functional-
ity are needed.
Because of these controversial data, the suitability of HDL-
cholesterol as a therapeutic target has been questioned [6]. Risk
stratiﬁed atherogenic lipoprotein burden (low-density lipoprotein
cholesterol and non-HDL-cholesterol) should remain the primary
and secondary targets of therapy in patients at cardiovascular risk
[6], as described by established guidelines. Plausible reasons forthe disappointing results of recent HDL-cholesterol raising thera-
pies are:
(i) Steady-state levels of HDL-cholesterol provide no informa-
tion on the rate of cholesterol-ﬂux from vascular macro-
phages to the liver, which is inﬂuenced by many factors
beyond the mass of HDL-cholesterol [10,62–64]. Moreover,
steady-state levels of HDL-cholesterol provide no informa-
tion on metrics of anti-inﬂammatory, anti-oxidant, anti-
thrombotic and endothelial function promoting activities
of HDL despite increasing evidence supporting the clinical
signiﬁcance of these pleiotropic functions [10,62–64].
(ii) Increasing the catabolism of HDL-cholesterol (e.g. by aug-
menting hepatic expression of SR-BI) has been shown to be
a positive regulator of cholesterol efﬂux from macrophages,
despite dramatically reduced HDL-cholesterol levels [65].
CETP inhibitors or niacin slow down HDL catabolism, there-
fore cholesterol efﬂux frommacrophages might be unaltered
or even decreased. Moreover, recent studies reported that
the addition of niacin to statin therapy did not improve met-
rics of HDL functionality despite signiﬁcant increases in
HDL-cholesterol [66]. This ﬁnding is in line with the obser-
vation that niacin and CETP inhibitors raise HDL-cholesterol
with little effect on HDL particle number [67]. In addition, a
recent multiethnic study suggested that HDL particle
number correlated better with HDL function than HDL-
cholesterol [68].
(iii) Levels of HDL-cholesterol in the circulation do not reﬂect the
pathobiology of a diseased artery wall. There is mounting
evidence that HDL isolated from human aortic tissues is
markedly distinct from those of circulating HDL. Speciﬁcally,
HDL in human aorta was found to be extensively crosslinked
[69] and rendered dysfunctional by myeloperoxidase-medi-
ated carbamylation of lysine residues and oxidation of
methionine and tryptophan residues [50,70,71].
(iv) There is strong evidence that inﬂammation profoundly
changes HDL composition, structure and function in the
bloodstream [8,10,63]. The functional heterogeneity inher-
ent to plasma HDL is driven in large part by its compositional
diversity [8–10]. Phospholipid depletion and enrichment
with pro-inﬂammatory proteins like serum amyloid A pro-
teins (SAA) or apoC-III generate dysfunctional or even pro-
atherogenic forms of HDL [56,72–76].
Taken together, it is becoming increasingly apparent that direct
measures of HDL composition and metrics of functionality are
needed.
2.5. HDL-mimetic infusion therapies
The ideal HDL-directed therapy would increase the amount of
functional HDL available to antagonize lipid deposition, inﬂamma-
tion, oxidation, and potential for thrombosis in the arterial wall.
Some clinical studies have suggested protective effects of HDL
infusions on coronary plaque burden when compared with base-
line [18–21]. However, interpretation is limited by the small sam-
ple sizes of those studies [18–21]. More recently, a well powered
prospective, randomized trial on infusion of the HDL-mimetic
agent CER-001 in coronary atherosclerosis patients was conducted
at centres in the USA, the Netherlands, Canada, and France [77].
Intravascular ultrasonography and quantitative coronary angiogra-
phy were performed at baseline and two to ﬁve weeks after the last
study infusion of the HDL-mimetic agent CER-001. Disappoint-
ingly, when compared with placebo, infusions of CER-001 did not
result in a signiﬁcant reduction in coronary atherosclerosis. The
failure of the study to achieve its primary efﬁcacy parameter is
Fig. 2. HDL protein hotspots changed in disease. The three diseases with most
reported changes are shown. All abbreviations are UniProt gene names. Proteins
which were reported to be signiﬁcantly changed (p < 0.05) in at least three studies
are listed. CAD, changes in coronary artery disease vs healthy subject HDL [80,84];
ESRD, changes in end stage renal disease vs healthy subject HDL [74,76,85]; PS/RA,
changes in psoriasis/rheumatoid arthritis vs healthy subject HDL [75,86]; all shown
in red; total, occurrence in all reported diseases shown in blue. Color intensity and
numbers refer to number of studies reporting signiﬁcant changes in protein
abundance.
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primary efﬁcacy parameters are: (i) the duration of the study could
have been too short and potentially favorable effects of infusion of
the HDL-mimetic agent CER-001 in the long term been overlooked.
(ii) The dosage could have been too low and/or not frequent
enough. (iii) As described above, the infused apoA-I might have
been rendered dysfunctional by myeloperoxidase-mediated carba-
mylation of lysine residues and oxidation of methionine and tryp-
tophan residues [50,70,71]. (iv) Moreover, a large fraction of the
phosphatidylcholine moiety of administered reconstituted HDL is
rapidly hydrolyzed by secretory phospholipases and LCAT in the
blood stream [78,79]. As a consequence, lysophosphatidylcholine
levels dramatically increase [78,79]. This raises the possibility that
the potent anti-inﬂammatory activity of administered reconsti-
tuted HDL may by counteracted by formed lysophospholipids.
Despite these negative results, the development of novel drugs
designed to modulate the serum levels and functionality of HDL
particles should continue, assuming the considerable amount of
basic scientiﬁc and clinical investigation demonstrating protective
activities of HDL in several animal models [6].
3. Recent advances in linking HDL composition to function
3.1. The toolbox of HDL-proteomics
Recent advances of mass spectrometry technology have dra-
matically increased our understanding of the proteomic diversity
of HDL. The Davidson Lab maintains an up to date list of all pub-
lished HDL proteins which even includes a ranking system based
on frequency observed (http://homepages.uc.edu/~davidswm/
HDLproteome.html). Depending on the method of HDL isolation,
upwards of 89 proteins have been identiﬁed repeatedly in inde-
pendent studies and the list continues to grow [8]. Among those
proteins are members of the complement pathway, immune func-
tion, protease inhibitors involved in hemostasis, acute phase
response proteins, and even metal-binding proteins in addition
to proteins consistent with traditionally accepted roles in lipid
transport [8,80]. This compositional diversity ﬁts well with studies
demonstrating a wide functional pleiotropy, including roles in lipid
transport, oxidation, inﬂammation, hemostasis and immunity.
Identiﬁcation of the HDL-proteome typically involves tryptic
digest of isolated particles, liquid chromatography coupled to tan-
dem mass spectrometry (LC–MS2) analysis of the resulting pep-
tides and public protein database search for matching peptides
and their fragment masses to proteins. While the number of pro-
teins identiﬁed on HDL particles is astonishing from a biology point
of view, state of the art proteomic methods are capable of identify-
ing and quantifying thousands of proteins.
Label free quantiﬁcation is often the method of choice to deter-
mine changes in protein abundance between different groups of
samples in the discovery phase [74–76,81–84]. The label free
quantiﬁcation technique applied in all these studies is called spec-
tral counting. It relies on the fact that mass spectrometers have
built in routines that trigger fragment (MS2) spectra based on the
abundance of precursor ions. Hence, more MS2 spectra will be
recorded for more abundant peptides and the identity of the pre-
cursor can be conﬁrmed with each of the MS2 spectra. While this
method allows robust quantiﬁcation of alterations as small as
20% for higher abundant proteins, the dynamic range of spectral
counting is limited and less abundant peptides require larger
changes to reach signiﬁcance. In the six published studies based
on spectral counting, in total 40 out of the 89 HDL proteins listed
by the Davidson Lab were found to be dysregulated between
experimental and control groups [74–76,81–84].
With increasing sample numbers and the need for more strin-
gent thresholds, stable isotope labeling techniques such as iTRAQ(i.e. isobaric Tags for Relative and Absolute Quantitation) become
attractive options [85,86]. iTRAQ uses isobaric (i.e. identical
mass/charge ratio) tags, that can only be distinguished on MS2
level. Individual samples are labeled with individual iTRAQ tags
(up to 8-plex), pooled and analyzed by LC–MS2. Since the tags
are isobaric, the same precursor ions of all mixed samples appear
as one signal in the full MS scan. However, as soon as the precursor
ions get fragmented, each of the iTRAQ tags shows a distinct frag-
ment, termed the reporter ion. It is therefore possible to calculate
the relative abundance of the precursors in the individual samples
by comparing the intensities of the individual reporter ions. While
the preparation of iTRAQ samples is more time consuming, there
are several advantages of the iTRAQ approach. First, the dynamic
range is improved compared to the spectral counting approach.
Also, the signiﬁcance threshold is independent of the analyte’s
abundance. Finally, by measuring several samples as one pool,
the instrument time is reduced. In the two published iTRAQ studies
44 out of the 89 HDL proteins listed by the Davidson Lab were
found to be dysregulated between experimental and control
groups. [85,86].
First attempts to span the gap to a more routine clinical setting
by multiplexed quantiﬁcation of a subset of HDL proteins by multi-
ple reaction monitoring mass spectrometry (MRM–MS) have been
made [87,88]. In MRM, the abundance of one (or more) fragment(s)
of each precursor of interest is measured under optimized condi-
tions. This allows quantiﬁcation of the precursors with high sensi-
tivity, high selectivity and a very high dynamic range. However, it
is a strictly targeted approach and any changes not covered by the
precursor list would remain unnoticed. Currently, MRM transitions
for 32 HDL proteins have been described [88].
3.2. HDL-proteome remodeling in disease
More recently, several research groups have started to assess
whether HDL proteomic composition is altered in CAD [56,80,84]
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[74,76], rheumatoid arthritis [86], type 2 diabetes [89], psoriasis
[75,90] and aging [83]. All studies reported multiple alterations
in the protein composition of HDL. Fig. 2 shows a heat map of
HDL proteins found to be changed in disease vs. control settings
by either label free or stable isotope labeling techniques visualizing
hot spots for HDL proteome changes in disease. Proteins involved
in lipid metabolism, transport and inﬂammation were mainly
affected. Especially proteins of the acute phase response and the
complement system were enriched on diseased HDL particles. In
contrast, some apolipoproteins were found to be enriched while
others were depleted (Table 1).
3.2.1. ApoA-I and apoA-II
Recent proteomic studies have shown a decrease in HDL associ-
ated apoA-I in chronic kidney disease, psoriasis and rheumatoid
arthritis [74–76,86]. Traditionally, the loss of HDL function has
been attributed to replacement of apoA-I by other proteins, notably
acute-phase proteins such as SAA, which in severe inﬂammation
can represent more than 50% of HDL proteins [91]. ApoA-I, the
major protein of HDL, is probably among the most intensively
studied of all proteins. It functions in HDL assembly, in the removal
of excess cholesterol from cells, and in the RCT. It is a cofactor for
LCAT [92], the enzyme responsible for cholesterol esteriﬁcation in
HDL, and it stabilizes certain antioxidant enzymes, such as serum
paraoxonase (PON1), that are carried on HDL [93]. Impaired LCAT
activity might be responsible for altered cholesterol hemostasisTable 1
Common proteomic features of dysfunctional HDL.
Proteins Known functions
ApoA-I  Major protein of HDL
 Lipid binding and transport
 Cofactor of LCAT
 Anti-oxidative properties
ApoA-II  2nd major protein of HDL
 Inhibitor of hepatic lipase
SAA1/SAA2  Major acute phase protein
 Pro-inﬂammatory properties
Complement C3  Cleaved into C3a & C3b
 C3a: mediator of local inﬂammation
 C3b: opsonizing factor
Hemoglobin, haptoglobin  Oxygen transport
 Hemoglobin binding
ApoA-IV  Modulates LPL
 Activator of LCAT
ApoC-II  Activates LPL
 Inhibitor of LCAT
ApoC-III  Inhibits LPL and HL
 Delays TGRL catabolism
 Ligand of TLR2
ApoM  Lipid transport
 Binds S1P and fatty acids
Clusterin  ATP-independent chaperone
 Inhibits apoptosis
PON1 activity  Hydrolyzes lactones, aromatic carbox
acid esters and organophosphates
Lp-PLA2 activity  Hydrolyzes PAF
 Ca2+-independent PLA2
 Phospholipid binding
The table summarizes identiﬁed alterations of the protein composition/activity of HDL
coronary syndrome; apo, apolipoprotein; CAD, coronary artery disease; ESRD, end-sta
acyltransferase; LPL, lipoprotein lipase; Lp-PLA2, lipoprotein associated phospholipase A2
serum amyloid A, S1P, sphingosine-1-phosphate; TGRL, triglyceride rich lipoprotein; TLof acute-phase HDL compared with native HDL. In contrast,
apoA-II, the second most abundant protein of HDL, has no known
function, and its presence on HDL has been reported to have no
inﬂuence on cholesterol efﬂux from cells, nor is it a cofactor for
any known enzyme [94]. ApoA-II enriched HDL particles are more
triglyceride enriched and resistant to reductions in size and apoA-I
content, suggesting inhibition of hepatic lipase by apoA-II [95]. A
loss of apoA-II was observed in chronic kidney disease and patients
suffering from rheumatoid arthritis, whereas increased apoA-II lev-
els were observed in HDL from psoriatic subjects [74–76,86,96].
3.2.2. SAA proteins
SAA proteins represent the hottest spot for HDL proteome
changes in diseases (Fig. 2). HDL derived from patients suffering
from chronic kidney disease, psoriasis, rheumatoid arthritis and
acute coronary syndrome was shown to be enriched in SAA [74–
76,80,83–86]. Enrichment of HDL with SAA is linked to decreased
apoA-I contents in line with the observation that SAA replaces
apoA-I on HDL under inﬂammatory conditions [97,98]. Triggered
by inﬂammation the concentrations of SAA may increase during
the acute-phase reaction to levels 1000-fold [99]. The SAA family
of proteins is encoded by multiple genes that display allelic varia-
tion and a high degree of homology in mammals. It has to be noted,
that the UniProt entry of SAA was only recently divided into the 2
individual entries for SAA1 and SAA2. Moreover, due to their high
degree of identity (93%), they are usually not distinguished in
proteomic studies in contrast to SAA4. SAA1/SAA2 increases theAlteration Reference
 ESRD
 Psoriasis, RA
[74–76,86]
 ESRD
 Diabetes
 Psoriasis
[74–76,86,89]
 ESRD, HD
 ACS
 Psoriasis, RA
[74–76,80,83–86]
 CAD
 Psoriasis, RA
 CAD
[75,80,83,84,86]
 ESRD
 Psoriasis, RA
 CAD
[75,80,83,84,86]
 ESRD
 CAD
[76,80,85]
 ESRD [74,76,85]
 ESRD
 CAD
[56,76,85]
 ESRD
 Diabetes
 Psoriasis
[75,76,89]
 CAD
 Diabetes
[56,80,121]
ylic  ESRD
 Diabetes
 CAD, ACS
 RA
 Psoriasis
 Heart disease
[48,49,83,86,89,96]
 Psoriasis
 ESRD
[75,76,96]
in inﬂammatory diseases identiﬁed in at least 3 independent studies. ACS, acute
ge renal disease; HD, hemodialysis; HL, hepatic lipase; LCAT, lecithin-cholesterol
; PAF, platelet activating factor; PON1, paraoxonase 1; RA, rheumatoid arthritis; SAA,
R2, Toll-like receptor 2.
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arterial intima thereby boosting the exposition to oxidative modi-
ﬁcations [100]. SAA1/SAA2 was shown to have chemoattractant
properties promoting migration, adhesion, and tissue inﬁltration
of monocytes and polymorphonuclear leukocytes [101]. The sub-
stitution of apoA-I and apoA-II by SAA1/SAA2 in uremic HDL neg-
atively correlated with the phospholipid content of HDL and
resulted in an impaired cholesterol acceptor capability of HDL
[76]. Of particular interest, SAA1/SAA2 was identiﬁed as being
responsible for the pro-inﬂammatory effects of HDL isolated from
chronic kidney disease patients, affecting cytokine production
and adhesion molecule expression on monocytes and myeloid den-
dritic cells [74].
In contrast to SAA1 and SAA2, SAA4 is reported to be expressed
constitutively. Under non-inﬂammatory conditions it accounts for
more than 90% of the total SAA content of HDL [102]. However its
function remains unknown. Despite the proposed constitutive
expression, it was reported to be increased in chronic kidney dis-
ease and rheumatoid arthritis [76,85,86] and decreased in psoriatic
subjects in one study [75].
3.2.3. Complement component 3, hemoglobin and haptoglobin
Increased levels of HDL associated complement C3 and HDL
associated hemoglobin and haptoglobin were identiﬁed in patients
with CAD, psoriasis and rheumatoid arthritis [75,80,83,84,86].
Complement C3 is produced by human monocyte-derived macro-
phages and contributes to innate immunity [103] and has been
suggested to contribute to vascular disease [104]. Concordantly,
the complement inhibitor clusterin is downregulated in disease
(see below). It is thought that haptoglobin is an acute-phase pro-
tein because haptoglobin sequesters the iron within hemoglobin,
preventing iron-utilizing bacteria from beneﬁting from hemolysis.
Both, hemoglobin and haptoglobin were shown to alter HDL func-
tionality rendering HDL pro-inﬂammatory [105].
3.2.4. ApoA-IV
ApoA-IV was reported to be up regulated in HDL from hemodi-
alysis and stable CAD patients [76,80,85]. In humans and the
majority of animal species, apoA-IV is synthesized primarily by
the intestine and to a lesser extent by the liver. It is present in
plasma, the lymph chylomicrons, and the cerebrospinal ﬂuid
[106]. Hydrolysis of the triglycerides of chylomicrons by lipopro-
tein lipase in plasma causes dissociation of apoA-IV and its redistri-
bution in HDL [106]. Although its primary function in human lipid
metabolism has not been established, ApoA-IV has been found to
modulate apoC-II [107] and to activate LCAT [108]. LCAT esteriﬁes
free cholesterol with phosphatidylcholine as an acyl-donor and is
therefore required for efﬁcient uptake of free cholesterol by HDL.
3.2.5. ApoC-II
ApoC-II was reported as up-regulated exclusively but consis-
tently in HDL of hemodialysis patients [74,76,85]. It is a co-factor
of lipoprotein lipase, thereby regulating triacylglycerol content of
HDL particles and missense mutations of apoC-II lead to hyperlip-
oproteinemia 1B [109]. The phenotype is indistinguishable from
lipoprotein lipase deﬁciency. Furthermore, apoC-II was reported
to inhibit LCAT activity [110].
3.2.6. ApoC-III
Enrichment with apoC-III in HDL of patients with chronic kid-
ney disease and CAD is another very robust observation in proteo-
mic studies from different laboratories [56,76,85]. ApoC-III acts as
a pro-inﬂammatory mediator and an endogenous ligand of Toll-
like receptor 2, which has been implicated in the aggravation of
atherosclerosis [111]. Previous experimental studies have shown
that apoC-III, an inhibitor of lipoprotein lipase and hepatic lipase,may be a crucial link between renal dyslipidemia and increased
atherosclerosis [112]. Strikingly, separating HDL according to
apoC-III identiﬁed two types of HDL with opposing associations
with risk of CAD. It was found that apoC-III-containing HDL was
associated with increased cardiovascular risk, whereas the apoC-
III-lacking fraction was associated with cardioprotection [113].
The proatherogenic effects of apoC-III, as a component of VLDL
and LDL, may therefore extend to HDL. Interestingly, subjects with
chronic kidney disease exhibit catabolic defects in apoC-III result-
ing in increased apoC-III plasma levels [114] resulting in high HDL
associated apoC-III levels observed in chronic kidney disease
patients. A recent study showed that HDL from CAD patients is
enriched in apoC-III thereby stimulating endothelial apoptotic
pathways [56]. The apoC-III levels of uremic HDL positively corre-
lated with HDL-associated triglycerides and negatively with the
phospholipid content of HDL. In addition, these compositional
alterations were associated with an impaired cholesterol acceptor
capability of HDL [76].
3.2.7. ApoM
A loss of apoMwas shown by different research groups in type 2
diabetes mellitus [89], chronic kidney disease [76] and psoriasis
[75]. Being a member of the lipocalin protein family, apoM is able
to sequester and transport low molecular weight compounds.
Myristic acid, palmitic acid and stearic acid, retinol, all-trans-reti-
noic acid and 9-cis-retinoic acid have been reported to bind to
apoM [115]. Moreover, it was recently shown that apoM mediates
the enrichment of sphingosine-1-phosphate content in HDL [116],
which promotes arterial vasodilation by stimulating endothelial
nitric oxide production and inhibiting monocyte recruitment into
the intima [39,117]. ApoM also plays a key role in cholesterol efﬂux
to HDL, at least in animal models [118]. Interestingly, transgenic
overexpression of apoM in mice leads to reduced atherosclerotic
lesions [119].
3.2.8. Clusterin
Two research groups observed a loss off clusterin in CAD
patients [56,80]. Clusterin, also known as apoJ, has been implicated
in a variety of activities including programmed cell death, regula-
tion of complement mediated cell lysis and acts as a complement
inhibitor [120]. Clusterin concentrations in HDL negatively associ-
ated with insulin resistance and anti-apoptotic activity of HDL,
implicating a protective role of HDL associated clusterin [56,121].
3.2.9. Paraoxonase 1
The activity of PON1, an important HDL associated enzyme, was
found to be decreased in HDL of patients with CAD [49], type 2 dia-
betes mellitus [89], chronic kidney disease [122–124], rheumatoid
arthritis [86] and psoriasis [96]. PON1 has been implicated in anti-
oxidant and anti-inﬂammatory functions [125,126], and its activity
has been related to cardiovascular risk [127]. A recent study dem-
onstrates that PON1 may interact with apoA-I and LCAT to inhibit
LDL oxidation, with the combination preventing LCAT inactivation
[29]. The decreased PON1 activity showed associations with
reduced anti-oxidative activities of HDL in various disease condi-
tions. One study suggested that low HDL associated PON1 activity
is involved in the inhibition of nitric oxide production in endothe-
lial cells [49], however this was not observed in a subsequent study
[48].
3.2.10. Lipoprotein associated phospholipase A2
The HDL-associated enzyme lipoprotein associated phospholi-
pase A2 (Lp-PLA2) is signiﬁcantly increased in psoriasis patients
and patients suffering from end-stage renal disease [75,76,96].
Lp-PLA2 has recently been associated with an enhanced risk of
CAD [128,129]. These ﬁndings led to the hypothesis that Lp-PLA2
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vascular disease. In circulation, Lp-PLA2 normally travels mainly
with LDL, but about 20% of Lp-PLA2 is associated with HDL. Inter-
estingly, Lp-PLA2 content of HDL negatively correlated with
phospholipid levels of HDL, suggesting that Lp-PLA2 hydrolyzes
short-chain phospholipids or oxidized-phospholipids in HDL. In
line with this observation, it was found that HDL associated Lp-
PLA2 activity, and lyso-phosphatidylcholine content signiﬁcantly
correlated with HDL-associated Lp-PLA2 mass in end-stage renal
disease patients [76].
3.3. Proteomics of HDL subclasses
The majority of the HDL proteomics studies so far have been
carried out assuming a homogenous HDL population. However it
has long been known that some HDL particles contain apoA-II
while others do not [130]. Moreover, even within the HDL popula-
tion, size differences do exist. Therefore, numerous attempts have
been made to deﬁne subclasses of spherical HDL. The probably
most common deﬁnition uses ﬁve subclasses of HDL. These are
HDL2b, HDL2a, HDL3a, HDL3b, and HDL3c, in order of decreasing
diameter and increasing density [4]. More recently a novel nomen-
clature based on the size of the particles was suggested: very large
HDL particles (VL-HDL), large HDL particles (L-HDL), medium HDL
particles (M-HDL), small HDL particles (S-HDL), and very small
HDL particles (VS-HDL) [131]. To our knowledge, only a single pro-
teomics publication so far compares healthy to diseased state on
an HDL subclass level. Gordon et al. investigated 12 size exclusion
fractions from lean, obese and type 2 diabetic subjects [89]. They
found that apoE was reduced almost ﬁvefold in type 2 diabetes
compared to lean, healthy subjects. Moreover, the distribution
maximum of apoE was shifted towards smaller particles in the
type 2 diabetes group. Also, less apoA-II and PON1 were found in
the type 2 diabetes group, with a more pronounced effect in larger
HDL subfractions.
3.4. The HDL lipidome
HDL particles are the smallest and densest of all lipoproteins.
The lipid fraction of HDL amounts for roughly 50% of the total
weight [9]. The amphipathic shell is formed by a single layer con-
sisting mainly of phospholipids and free cholesterol, whereas the
core consists of neutral lipids such as cholesteryl-esters and tria-
cylglycerols. Phospholipids predominate, accounting for 40–60%
of total lipids, followed by cholesteryl-esters (30–40%), triacylgly-
cerols (5–12%) and free cholesterol (5–10%) [9]. Lipidomic
approaches have provided novel insights into the HDL lipidome
and over 160 individual molecular lipids species were identiﬁed
in HDL isolated from healthy subjects [9].
HDL subclasses differ in the ratio of shell to core lipids, as well
as in the composition within the amphipathic and neutral lipids.
While the shells of large HDL particles tend to be enriched with
sphingomyelins and ceramides, small particles have more phos-
phatidylserine, phosphatidic acid and phosphatidylcholine present
on their surface. Moreover, the very small particles are enriched in
lyso-phosphatidylcholine and depleted of free cholesterol [132].
Also the side chain distribution is shifted towards more unsatu-
rated moieties in smaller particles [9]. These changes do not only
inﬂuence the physical properties such as surface charge and mem-
brane ﬂuidity of the particles, but also their biological functions.
The smaller HDL particles have a higher capability to stimulate
cholesterol efﬂux from macrophages and their anti-oxidative
potential to protect LDL and pro-thrombotic compounds such as
thromboxane B2 and p38-MAPK from oxidation is higher. Also,
anti-inﬂammatory and anti-apoptotic protective functions are
more pronounced in the small and very small subpopulations[132]. On the other hand, a recent study observed that decreased
large HDL particles isolated from type 2 diabetics inversely corre-
lated with vascular stiffness assessed by pulse wave velocity
[89]. Yet another study found a signiﬁcant shift in average HDL
particle size only for type 2 diabetes combined with dyslipidemia,
while the normolipidemic type 2 diabetes group showed the same
average HDL particle size as the healthy control group [133].
It is therefore becoming increasingly apparent that HDL-choles-
terol alone is not a suitable marker for CAD risk assessment, while
HDL particle number and especially subpopulation distribution
might be better suited to fulﬁll this task [7,63] .
3.5. HDL composition and function: novel biomarker with implications
for vascular wall biology
HDL in inﬂammatory disease states is enriched in proteins that
play critical roles in macrophage biology, lipid metabolism, and the
inﬂammatory response (Table 1). Several of these proteins are
produced by cholesterol-loaded macrophages, suggesting that a
fraction of the proteins that are overproduced under inﬂammatory
conditions might be derived from macrophages in atherosclerotic
lesions. Alternatively, inﬂammation may enhance their production
by the liver and promote their association with circulating HDL.
Signiﬁcant increases in SAA, apoA-IV, apoC-III and complement
C3 levels and loss of atheroprotective apoA-I, apoM and clusterin
indicate a signiﬁcant shift to an inﬂammatory proﬁle and may pro-
vide clues to the overall metabolic processes that underlie these
diseases. HDL associated enzymatic activities in disease states
and antioxidative activities of HDL are altered in disease states.
Inﬂammation is associated with low HDL associated paraoxonase
activity whereas Lp-PLA2 activity is increased in chronic kidney
disease and psoriasis (Table 1). Notably, proteomic analysis did
not consistently provide evidence for a reduction in PON1 mass,
suggesting that inﬂammation alters enzymatic activity. Previous
studies demonstrated that HDL associated PON1 is rapidly inacti-
vated by neutrophil derived reactive species [50,134]. In particular,
leukocyte released myeloperoxidase has emerged as an enzymatic
catalyst that promotes HDL oxidation and carbamylation in vivo
[50,71,135–137]. In addition to HDL proteomics, HDL lipidomics
is expected to signiﬁcantly add to the identiﬁcation of mediators
and biomarkers of normal and dysfunctional HDL. The HDL phos-
pholipidome exhibits signiﬁcant correlations with multiple metrics
of HDL function [132]. HDL isolated from subjects with chronic kid-
ney disease and psoriasis showed decreased levels of phospholip-
ids that strongly associated with a reduced ability to promote
RCT [75,76,96]. HDL-triacylglycerol content negatively correlated
with cholesterol efﬂux potential of uremic HDL [76]. However,
more detailed and quantitative analyses of alterations in the lipid
moiety of HDL are warranted and will contribute to an improved
understanding of impaired HDL particle formation, maturation
and function.
4. Conclusion
Several studies have clearly shown that the composition of HDL
can change in a variety of disease states and these alterations affect
metrics of HDL functionality. These recent ﬁndings suggest that
distinct disease states harbor a characteristic disease-speciﬁc
HDL proteome. It remains to be seen whether these changes in
HDL composition contribute to the disease etiology or if these
changes are secondary to other processes occurring during disease
progression. However, there is still a substantial need for valida-
tion and extension of those recent observations. HDL proteomic
analysis is yet in its early years, and general conclusions about
the HDL proteome as a biomarker for disease are limited by the
small number of published studies. Moreover, differences in
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HDL composition and function. Future attempts will be targeted
towards improving isolation procedures, differentiating between
HDL subclasses as well as protein isoforms. These recent studies
clearly illustrate the promise of HDL proteomics for deriving new
biomarkers for disease diagnosis and to measure the effectiveness
of current and future treatment regimens.
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